Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Investigation

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/JCI83731PMID 28436937PMCID PMC5451251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction

  2016cited by this paper
• Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia.

  2016cited by this paper
• Alkaline Phosphatase and Hypophosphatasia

  2015cited by this paper
• The Anti‐Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5

  2015cited by this paper
• Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases

  2014influential reference
• Molecular Evolution of the Tissue-nonspecific Alkaline Phosphatase Allows Prediction and Validation of Missense Mutations Responsible for Hypophosphatasia*

  2014cited by this paper
• Using ancestry-informative markers to identify fine structure across 15 populations of European origin

  2014cited by this paper
• Romosozumab in postmenopausal women with low bone mineral density

  2014influential reference
• Clinical and Radiographic Findings in Adults With Persistent Hypophosphatasemia

  2014cited by this paper
• Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double‐blind, placebo‐controlled study

  2014cited by this paper
• Single‐ and Multiple‐Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women

  2014cited by this paper
• Osteoblast-Specific Krm2 Overexpression and Lrp5 Deficiency Have Different Effects on Fracture Healing in Mice

  2014cited by this paper
• Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia

  2014cited by this paper
• Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma

  2013cited by this paper
• WNT signaling in bone homeostasis and disease: from human mutations to treatments

  2013cited by this paper
• The P2Y13 receptor regulates extracellular ATP metabolism and the osteogenic response to mechanical loading

  2013cited by this paper
• Enzyme-replacement therapy in life-threatening hypophosphatasia.

  2012cited by this paper
• The Transcriptional Profile of Mesenchymal Stem Cell Populations in Primary Osteoporosis Is Distinct and Shows Overexpression of Osteogenic Inhibitors

  2012cited by this paper
• “Atypical femoral fractures” during bisphosphonate exposure in adult hypophosphatasia

  2012cited by this paper
• The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: The role of p2x receptors.

  2012cited by this paper
• A2B Adenosine Receptor Promotes Mesenchymal Stem Cell Differentiation to Osteoblasts and Bone Formation in Vivo*

  2012cited by this paper
• Failure of Teriparatide in Treatment of Bone Complications of Adult Hypophosphatasia

  2012cited by this paper
• Hypophosphatasia: Enzyme Replacement Therapy (Asfotase Alfa) Decreases TNSALP Substrate Accumulation And Improves Functional Outcomes In Affected Adolescents And Adults.

  2012cited by this paper
• Sclerostin: a novel target for intervention in the treatment of osteoporosis.

  2011cited by this paper
• Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

  2011cited by this paper
• Functional characterization of a novel mutation localized in the start codon of the tissue-nonspecific alkaline phosphatase gene.

  2011cited by this paper
• Skeletal mineralization defects in adult hypophosphatasia—a clinical and histological analysis

  2011cited by this paper
• Parathyroid hormone treatment improves pain and fracture healing in adult hypophosphatasia.

  2010cited by this paper
• Lack of sustained response to teriparatide in a patient with adult hypophosphatasia.

  2010cited by this paper
• Inorganic pyrophosphate as a regulator of hydroxyapatite or calcium pyrophosphate dihydrate mineral deposition by matrix vesicles.

  2009cited by this paper
• Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis

  2009cited by this paper
• Characterization of the Structural Features and Interactions of Sclerostin

  2009cited by this paper
• Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles

  2009cited by this paper
• Teriparatide treatment in adult hypophosphatasia in a patient exposed to bisphosphonate: a case report.

  2009cited by this paper
• Glycosylation differences contribute to distinct catalytic properties among bone alkaline phosphatase isoforms.

  2009cited by this paper
• TNAP, TrAP, ecto‐purinergic signaling, and bone remodeling

  2008cited by this paper
• Hypophosphatasia.

  2008cited by this paper
• A new mechanism of dominance in hypophosphatasia: the mutated protein can disturb the cell localization of the wild-type protein

  2008cited by this paper
• Treatment of adult hypophosphatasia with teriparatide.

  2008cited by this paper
• Adult hypophosphatasia treated with teriparatide.

  2007cited by this paper
• Enzyme Replacement Therapy for Murine Hypophosphatasia

  2007cited by this paper
• Conclusion

  2006cited by this paper
• Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice.

  2004cited by this paper
• A molecular approach to dominance in hypophosphatasia

  2001cited by this paper
• Asp361Val Mutant of alkaline phosphatase found in patients with dominantly inherited hypophosphatasia inhibits the activity of the wild-type enzyme.

  2000cited by this paper
• Hypophosphatasia

  1964cited by this paper

• Therapie und Management der Hypophosphatasie im Erwachsenenalter: Differenzierte Therapieansätze in Abhängigkeit vom Krankheitsverlauf

  2026cites this paper
• Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa

  2025cites this paper
• Diagnostik und Therapie der Hypophosphatasie im Kindes- und Jugendalter

  2025cites this paper
• Hypophosphatasia: 90 Years from a Canadian Discovery—A Comprehensive Review of the ALPL Gene Underlying Rathbun’s Syndrome

  2025cites this paper
• Hypophosphatasia: A case report

  2025cites this paper
• Ormoni e citochine ossei target delle terapie dei disordini osteometabolici e dell’osteoporosi

  2024cites this paper
• Monoclonal antibody anti-sclerostin for treatment of pelvic insufficiency fractures in adult hypophosphatasia: A case report

  2024cites this paper
• Anti-sclerostin antibody – A potential therapeutic target for periodontal bone regeneration

  2024cites this paper
• Τhe story of sclerostin inhibition: the past, the present, and the future

  2024cites this paper
• Hypophosphatasia: from birth to adulthood

  2023cites this paper
• Musculoskeletal and neurocognitive clinical significance of adult hypophosphatasia

  2023cites this paper
• Treatment of hypophosphatasia

  2023cites this paper
• Effects of asfotase alfa in adults with pediatric-onset hypophosphatasia over 24 months of treatment.

  2023cites this paper
• Hypophosphatasie im Kindesalter

  2023cites this paper
• The effect of osteoporosis treatment on bone mass.

  2022cites this paper
• Gene Therapy Using Recombinant AAV Type 8 Vector Encoding TNAP‐D10 Improves the Skeletal Phenotypes in Murine Models of Osteomalacia

  2022cites this paper
• Novel Therapeutic Agents for Rare Diseases of Calcium and Phosphate Metabolism.

  2022cites this paper
• Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders

  2022cites this paper
• Wnt signaling: Essential roles in osteoblast differentiation, bone metabolism and therapeutic implications for bone and skeletal disorders

  2022cites this paper
• Proposing a clinical algorithm for better diagnosis of hypophosphatasia in resource-limiting situations

  2022cites this paper
• The Role of Sclerostin in Bone Diseases

  2022cites this paper
• Bilateral atypical femoral fractures during denosumab therapy in a patient with adult-onset hypophosphatasia

  2021cites this paper
• TNAP as a New Player in Chronic Inflammatory Conditions and Metabolism

  2021cites this paper
• New therapeutic options for bone diseases

  2021cites this paper
• Predictive modeling of hypophosphatasia based on a case series of adult patients with persistent hypophosphatasemia

  2021cites this paper
• Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application

  2021cites this paper
• Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones

  2021cites this paper
• Cardiovascular Safety and Sclerostin Inhibition - a mini-review.

  2021cites this paper
• Seltene osteologische Erkrankungen und ihre Therapie

  2021cites this paper
• Hypophosphatasia: A Unique Disorder of Bone Mineralization

  2021cites this paper
• Gene Therapy Using Adeno‐Associated Virus Serotype 8 Encoding TNAP‐D10 Improves the Skeletal and Dentoalveolar Phenotypes in Alpl −/− Mice

  2021cites this paper
• Hypophosphatasia

  2021cites this paper
• Endocrinology of bone mineralization: an update.

  2021cites this paper
• Adult hypophosphatasia with a novel ALPL mutation: Report of an Indian kindred

  2020cites this paper
• Therapie der Hypophosphatasie

  2020cites this paper
• Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases

  2020cites this paper
• Adult hypophosphatasia manifests in a marathon runner

  2020cites this paper
• Ionomycin ameliorates hypophosphatasia via rescuing alkaline phosphatase deficiency-mediated L-type Ca2+ channel internalization in mesenchymal stem cells

  2020cites this paper
• Pharmacologic basis of sclerostin inhibition

  2020cites this paper
• Bone mineral density and fracture risk in adult patients with hypophosphatasia

  2020cites this paper
• Therapie der Hypophosphatasie Treatments for Hypophosphatasia

  2020cites this paper
• Phage Display Derived Monoclonal Antibodies: From Bench to Bedside

  2020cites this paper
• Sclerostin and Wnt Antagonists: Implications for Osteoporosis Therapies

  2020cites this paper
• Seltene Erkrankungen in der Pädiatrie – von der Diagnostik und Behandlung einzelner Erkrankungen zum Aufbau von Netzwerkstrukturen

  2020cites this paper
• Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment

  2020cites this paper
• Looking for new anabolic treatment from rare diseases of bone formation.

  2020cites this paper
• Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics

  2020cites this paper
• Hypophosphatasia: Current Literature for Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment

  2020cites this paper
• The Regulation of Bone Metabolism and Disorders by Wnt Signaling

  2019cites this paper
• Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering.

  2019cites this paper
• Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin.

  2019cites this paper
• Schwerpunktthema : Seltene Knochenerkrankungen

  2019cites this paper
• L’hypophosphatasie

  2019cites this paper
• The evolving therapeutic landscape of genetic skeletal disorders

  2019influential citation
• Romosozumab: a novel bone anabolic treatment option for osteoporosis?

  2019cites this paper
• Hypophosphatasie: Symptome, Diagnose, Therapie

  2019cites this paper
• Alkaline Phosphatase Replacement Therapy.

  2019cites this paper
• Outcome of Teriparatide Treatment on Fracture Healing Complications and Symptomatic Bone Marrow Edema in Four Adult Patients With Hypophosphatasia

  2019cites this paper
• Ionomycin Ameliorates Hypophosphatasia via Rescuing Alkaline Phosphatase Deficiency-mediated L-type Ca2+ Channel Internalization in Mesenchymal Stem Cells

  2019cites this paper
• Sclerostin-Antikörper als neue Therapieoption der Osteoporose

  2019cites this paper
• Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy

  2018cites this paper
• The Expanding Life and Functions of Osteogenic Cells: From Simple Bone‐Making Cells to Multifunctional Cells and Beyond

  2018influential citation
• Bone: best papers of the year 2017

  2018cites this paper
• Sclerostin Deficiency Alters Peripheral B Lymphocyte Responses in Mice

  2018cites this paper
• Hypophosphatasie

  2018cites this paper
• Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.

  2018cites this paper
• Abnormal bone turnover in individuals with low serum alkaline phosphatase

  2018cites this paper
• Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway

  2018cites this paper
• Hypophosphatasia: From Diagnosis to Treatment

  2018cites this paper
• Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations

  2017cites this paper